Glenmark Pharmaceuticals plans to create a manufacturing facility in Monroe, NC, the first in the United States for the Mumbai, India-based company, according to a press release.
The company has several new molecules in development, with its primary focus on areas of inflammation, including asthma, COPD and rheumatoid arthritis, and neuropathic and inflammatory pain, the release said.
Glenmark’s North American subsidiary, Glenmark Generics, has a portfolio of 90 products authorized for distribution in the US focused on dermatology, hormones, controlled substances, oncology and modified release products.
The 100,000 square-foot facility is expected to begin manufacturing operations at the end of the 2014-15 fiscal year, according to the release.
